When aberrantly expressed, Cripto can drive tumor initiation and progression in multiple tumor types, including prostate cancer [2], breast cancer [3], colon cancer [4], hepatocellular carcinoma [5], glioblastoma [6], and lung cancer [7]. The gene discussed is CRIPTO; the disease is neoplasm.